Drug intelligence / Profile preview

LuXBiome

Development stage: Preclinical
Lead developer: LuxBiome
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

LuXBiome (럭시보) is a preclinical-stage microbiome therapeutic candidate being developed by LuxBiome, a South Korean biotechnology company founded by a professor from Chung-Ang University. Discovered through a proprietary pangenome-mining AI platform, LuXBiome is designed as a next-generation "medifood" or innovative microbiome drug solution. The therapy specifically targets four major intestinal viruses to treat or prevent intestinal viral infections. The developer positions this asset as a first-in-class microbiome therapeutic, utilizing specific microbial components or metabolites identified via AI to provide a therapeutic effect in the gastrointestinal tract.

Other names: 럭시보

Beyond the preview

Go deeper on LuXBiome.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LuXBiome.

Explore the full profile